NASD · Healthcare · Medical Devices · USA
Outset Medical Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.
Outset Medical develops the Tablo Hemodialysis System, an FDA-cleared dialysis solution for hospitals, clinics, and home settings. The compact console integrates water purification and dialysate production with cloud connectivity, enabling remote monitoring and analytics for healthcare providers treating acute kidney injury and chronic kidney disease patients.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Outset Medical Inc stock.
Overvalued: intrinsic value $1.88 per share, market price $3.16, margin of safety -68.4% (as of 2026-11-17).
A 0.8x revenue multiple, discounted for its losses, values the shares at $1.88; the price of $3.16 is 68% above that value.
7 more funds hold it; the full list is part of the paid plan.
All 140 Medical Devices stocks
34 more in this industry show a wider margin of safety.
OM is overvalued (as of the 2026-11-17 close). A 0.8x revenue multiple, discounted for its losses, values the shares at $1.88; the price of $3.16 is 68% above that value.
$1.88 per share (as of the 2026-11-17 close), against a market price of $3.16. That is a margin of safety of -68.4%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.